Kuros Biosciences (XSWX:KURN) Quality Rank


XSWX:KURN Kuros Biosciences Ltd XSWX:KURN
64 GF Score
Price CHF21.16
GF Value CHF39.21
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Kuros Biosciences Quality Rank Related Terms

XSWX:KURN
64GF Score
Kuros Biosciences Ltd XSWX:KURN
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kuros Biosciences (XSWX:KURN) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of CHF21.16 is trading 46% below its estimated GF Value™ of CHF39.21. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for XSWX:KURN:

  • Quality Rank:
  • GF Value™: CHF39.21 vs. price of CHF21.16 (46% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the XSWX:KURN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
64GF Score

Get the complete analysis for XSWX:KURN

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF21.16
Price
CHF39.21
GF Value